BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 36166472)

  • 21. Optimal use of colonoscopy and fecal immunochemical test for population-based colorectal cancer screening: a cost-effectiveness analysis using Japanese data.
    Sekiguchi M; Igarashi A; Matsuda T; Matsumoto M; Sakamoto T; Nakajima T; Kakugawa Y; Yamamoto S; Saito H; Saito Y
    Jpn J Clin Oncol; 2016 Feb; 46(2):116-25. PubMed ID: 26685321
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effectiveness, benefit harm and cost effectiveness of colorectal cancer screening in Austria.
    Jahn B; Sroczynski G; Bundo M; Mühlberger N; Puntscher S; Todorovic J; Rochau U; Oberaigner W; Koffijberg H; Fischer T; Schiller-Fruehwirth I; Öfner D; Renner F; Jonas M; Hackl M; Ferlitsch M; Siebert U;
    BMC Gastroenterol; 2019 Dec; 19(1):209. PubMed ID: 31805871
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effectiveness analysis of colonoscopy and fecal immunochemical testing for colorectal cancer screening in China.
    Ren Y; Zhao M; Zhou D; Xing Q; Gong F; Tang W
    Front Public Health; 2022; 10():952378. PubMed ID: 36033786
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness of colorectal cancer screening programmes using sigmoidoscopy and immunochemical faecal occult blood test.
    Senore C; Hassan C; Regge D; Pagano E; Iussich G; Correale L; Segnan N
    J Med Screen; 2019 Jun; 26(2):76-83. PubMed ID: 30180780
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness analysis of colorectal cancer screening in a low incidence country: The case of Saudi Arabia.
    Naber SK; Almadi MA; Guyatt G; Xie F; Lansdorp-Vogelaar I
    Saudi J Gastroenterol; 2021; 27(4):208-216. PubMed ID: 33835054
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost Effectiveness of Screening Individuals With Cystic Fibrosis for Colorectal Cancer.
    Gini A; Zauber AG; Cenin DR; Omidvari AH; Hempstead SE; Fink AK; Lowenfels AB; Lansdorp-Vogelaar I
    Gastroenterology; 2018 Feb; 154(3):556-567.e18. PubMed ID: 29102616
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Would initiating colorectal cancer screening from age of 45 be cost-effective in Germany? An individual-level simulation analysis.
    Lwin MW; Cheng CY; Calderazzo S; Schramm C; Schlander M
    Front Public Health; 2024; 12():1307427. PubMed ID: 38454984
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and cost-effectiveness of fecal immunochemical test versus colonoscopy in colorectal cancer screening: a systematic review and meta-analysis.
    Zhong GC; Sun WP; Wan L; Hu JJ; Hao FB
    Gastrointest Endosc; 2020 Mar; 91(3):684-697.e15. PubMed ID: 31790657
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness of colorectal cancer screening in Slovakia.
    Babela R; Orsagh A; Ricova J; Lansdorp-Vogelaar I; Csanadi M; De Koning H; Reckova M
    Eur J Cancer Prev; 2022 Sep; 31(5):415-421. PubMed ID: 34789653
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative Effectiveness and Cost Effectiveness of a Multitarget Stool DNA Test to Screen for Colorectal Neoplasia.
    Ladabaum U; Mannalithara A
    Gastroenterology; 2016 Sep; 151(3):427-439.e6. PubMed ID: 27311556
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Estimating the impact of differential adherence on the comparative effectiveness of stool-based colorectal cancer screening using the CRC-AIM microsimulation model.
    Piscitello A; Saoud L; Fendrick AM; Borah BJ; Hassmiller Lich K; Matney M; Ozbay AB; Parton M; Limburg PJ
    PLoS One; 2020; 15(12):e0244431. PubMed ID: 33373409
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Optimizing screening with faecal immunochemical test for both sexes - Cost-effectiveness analysis from Finland.
    Heinävaara S; Gini A; Sarkeala T; Anttila A; de Koning H; Lansdorp-Vogelaar I
    Prev Med; 2022 Apr; 157():106990. PubMed ID: 35150749
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term benefits and harms of early colorectal cancer screening in German individuals with familial cancer risk.
    Sroczynski G; Hallsson LR; Mühlberger N; Jahn B; Rehms R; Hoffmann S; Crispin A; Lindoerfer D; Mansmann U; Siebert U
    Int J Cancer; 2024 Feb; 154(3):516-529. PubMed ID: 37795630
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Health Benefits and Cost-Effectiveness of Children's Oncology Group Breast Cancer Screening Guidelines for Chest-Irradiated Hodgkin Lymphoma Survivors.
    Wong FL; Lee JM; Leisenring WM; Neglia JP; Howell RM; Smith SA; Oeffinger KC; Moskowitz CS; Henderson TO; Mertens A; Nathan PC; Yasui Y; Landier W; Armstrong GT; Robison LL; Bhatia S
    J Clin Oncol; 2023 Feb; 41(5):1046-1058. PubMed ID: 36265088
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-effectiveness of one versus two sample faecal immunochemical testing for colorectal cancer screening.
    Goede SL; van Roon AH; Reijerink JC; van Vuuren AJ; Lansdorp-Vogelaar I; Habbema JD; Kuipers EJ; van Leerdam ME; van Ballegooijen M
    Gut; 2013 May; 62(5):727-34. PubMed ID: 22490518
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Costs and Benefits of Risk Stratification for Colorectal Cancer Screening Based On Phenotypic and Genetic Risk: A Health Economic Analysis.
    Thomas C; Mandrik O; Saunders CL; Thompson D; Whyte S; Griffin S; Usher-Smith JA
    Cancer Prev Res (Phila); 2021 Aug; 14(8):811-822. PubMed ID: 34039685
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-Effectiveness of Personalized Screening for Colorectal Cancer Based on Polygenic Risk and Family History.
    Cenin DR; Naber SK; de Weerdt AC; Jenkins MA; Preen DB; Ee HC; O'Leary PC; Lansdorp-Vogelaar I
    Cancer Epidemiol Biomarkers Prev; 2020 Jan; 29(1):10-21. PubMed ID: 31748260
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness analysis of colorectal cancer screening using colonoscopy, fecal immunochemical test, and risk score.
    Sekiguchi M; Igarashi A; Sakamoto T; Saito Y; Esaki M; Matsuda T
    J Gastroenterol Hepatol; 2020 Sep; 35(9):1555-1561. PubMed ID: 32167186
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Real-world cost-effectiveness of stool-based colorectal cancer screening in a Medicare population.
    Fisher DA; Karlitz JJ; Jeyakumar S; Smith N; Limburg P; Lieberman D; Fendrick AM
    J Med Econ; 2021; 24(1):654-664. PubMed ID: 33902366
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.